NewsBenzingaStoneX hält an der Kaufempfehlung für OmniAb fest und erhöht das Kursziel auf 6 $ StoneX hält an der Kaufempfehlung für OmniAb fest und erhöht das Kursziel auf 6 $ Benzinga 2026.10.07 13:22 (GMT+0) Open on Benzinga Other news Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights Palantir: Higher Fair Value, But Not Enough (NASDAQ:PLTR) Ambarella: The Biggest AI Growth Opportunity Is Still Ahead (NASDAQ:AMBA) Alphabet's President of Global Affairs and Chief Legal Officer dismisses Europe's concerns over US dominance in AI Activist Investor Starboard Takes Stake in Solstice, Demands $100M in Cost Cuts - TipRanks.com Gold (XAU:USD) Technical And Macro Outlook: October 2026
Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights
Alphabet's President of Global Affairs and Chief Legal Officer dismisses Europe's concerns over US dominance in AI
